Vitamin E analogs trigger apoptosis in HER2/erbB2-overexpressing breast cancer cells by signaling via the
Xiu-Fang Wang1, Paul K Witting, Brian A Salvatore
1Apoptosis Research Group, School of Health Science, Griffith University, Southport, Qld, Australia.
Abstract:
Alpha-tocopheryl succinate (alpha-TOS) is a redox-silent vitamin E (VE) analog with high pro-apoptotic and anti-neoplastic activity. Here we investigated whether alpha-TOS and several novel VE analogs kill breast cancer cells over-expressing the anti-apoptotic receptor protein HER2/erbB2. The agents induced apoptosis at comparable levels in both erbB2-low and -high cells. Generation of reactive oxygen species (ROS) preceded mitochondrial destabilization and execution of apoptosis, as evidenced by the anti-apoptotic effects of exogenous superoxide dismutase and mitochondrially targeted coenzyme Q. Dissipation of DeltaPsi(m) was followed by cytochrome c and Smac/Diablo re-localization and caspase-dependent cleavage of death substrate. A resistance to apoptosis for the corresponding rho(0) counterparts confirmed a critical dependency for mitochondria during the induction of apoptosis in breast cancer cells mediated by VE analogs and linked apoptosis to generation of radicals as judged by the delayed accumulation of ROS in the cybrid cell types. We conclude that alpha-TOS causes efficient apoptosis in breast cancer cells independent of their erbB2 status. Since erbB2 is frequently over-expressed in breast cancers and renders the neoplastic disease resistant to established treatment, our findings are of clinical interest.
Insights
Alpha-tocopheryl succinate (alpha-TOS), a vitamin E analog, effectively induces cancer cell death (apoptosis) in breast cancer cells, regardless of HER2/erbB2 protein levels. This finding is significant for developing new cancer treatments.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- Vitamin E (VE) analogs, like alpha-tocopheryl succinate (alpha-TOS), exhibit anti-neoplastic properties.
- HER2/erbB2 overexpression is common in breast cancers, contributing to treatment resistance.
Purpose of the Study:
- To investigate the efficacy of alpha-TOS and novel VE analogs in inducing apoptosis in breast cancer cells with varying HER2/erbB2 expression levels.
- To elucidate the mechanisms underlying VE analog-induced apoptosis in breast cancer cells.
Main Methods:
- Treatment of breast cancer cells (erbB2-low and -high) with alpha-TOS and VE analogs.
- Assessment of apoptosis, reactive oxygen species (ROS) generation, and mitochondrial membrane potential (DeltaPsi(m)).
- Use of superoxide dismutase, mitochondrially targeted coenzyme Q, and rho(0) cells to confirm mechanisms.
Main Results:
- Alpha-TOS and VE analogs induced apoptosis comparably in both erbB2-low and -high cells.
- Apoptosis was preceded by ROS generation and mitochondrial destabilization (DeltaPsi(m) dissipation).
- Mitochondrial dependence and radical generation were confirmed as critical for VE analog-mediated apoptosis.
Conclusions:
- Alpha-tocopheryl succinate effectively induces apoptosis in breast cancer cells irrespective of HER2/erbB2 expression.
- The findings suggest alpha-TOS as a potential therapeutic agent for breast cancers, including those resistant to conventional treatments due to HER2/erbB2 overexpression.
Related Concept Videos
Mitogens and the Cell Cycle
The Intrinsic Apoptotic Pathway
Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
MAPK Signaling Cascades
The Extrinsic Apoptotic Pathway
Cellular Injury V: Apoptosis and Autophagy
